Effects of an isopropanolic extract of Cimicifuga racemosa on urinary crosslinks and other parameters of bone quality in an ovariectomized rat model of osteoporosis.
A potential bone-sparing effect of Rhizoma actaeae (= cimicifugae) racemosae (black cohosh) was evaluated in ovariectomized Sprague-Dawley rats. The rats were ovariectomized at 12 weeks of age (body weight, 219-226 g) and placed on a soy-free diet 6 days after surgery. Animals were randomly assigned the following groups: control (n = 10), soy-free diet only; RAL (n = 10), soy-free diet plus raloxifene 3 mg/kg intragastrically; and REM (n = 10), soy-free diet supplemented with an isopropanolic black cohosh extract (Remifemin) with a daily intake of 4500 micro g triterpeneglycosides. Urinary levels of pyridinoline (PYR) and deoxypyridinoline (DPY), specific markers for bone loss, were measured at baseline and at weekly intervals. At the end of the study, the animals were killed and bone loss was determined by volumetric bone mineral density (BMD) measurements and peripheral quantitative computed tomography (pQCT). Mechanical resistance to fracture was also determined. Results demonstrated that an isopropanolic extract of black cohosh significantly diminished the urinary content of PYR and DPY and the morphometric correlates of bone loss associated with ovariectomy in rats. Reversal of the effects of ovariectomy on bone loss began 2-5 weeks after the start of treatment and continued through at least 7 weeks. Results similar in quality and magnitude were obtained in the group treated with raloxifene, a known selective estrogen receptor modulator (SERM). Because extracts of black cohosh are already recognized as safe and effective in the treatment of certain gynecological disorders, a longer-term clinical trial of this herbal remedy for the treatment of osteoporosis is warranted.
Schaper & Brümmer, R&D-Veterinary Medicine, Bahnhofstr. 35, 38259 Salzgitter, Germany.
Thomas
T
Nisslein
Johannes
J
Freudenstein
D019840:2-Propanol / Q000737:chemistry; D000596:Amino Acids / Q000652:urine; D000818:Animals; D015519:Bone Density; D001842:Bone and Bones / Q000187:drug effects; D031885:Cimicifuga / Q000737:chemistry*; D005260:Female; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology / Q000652:urine; D010052:Ovariectomy; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use; D020849:Raloxifene Hydrochloride / Q000494:pharmacology; D051381:Rats
D000596:Amino Acids; D010936:Plant Extracts; D020849:Raloxifene Hydrochloride; C015484:pyridinoline; D019840:2-Propanol